Molbio Diagnostics Reports Rs 52.7 Crore Profit in First Quarter Post-IPO

Molbio Diagnostics, a recent entrant to the stock market, has reported a significant profit of Rs 52.74 crore for the first quarter ending June 2026. This marks a notable turnaround from the Rs 23.94 crore loss recorded in the same period last year. The company's financial resurgence is largely attributed to the increased sales volume of its flagship product, the Truenat test-kit.

Strong Financial Performance Following IPO

After raising approximately Rs 940 crore through an Initial Public Offering (IPO) and listing on the stock exchange on August 17, Molbio Diagnostics has shown robust financial performance. The company's total income soared to Rs 411.48 crore in Q1, a substantial increase from Rs 100.47 crore in the corresponding period of the previous fiscal year. This growth is primarily driven by the widespread adoption of Truenat test-kits.

Truenat Test-Kit Sales Surge

The Truenat test-kit, designed to quickly and accurately detect a variety of infectious diseases at the point of care, has seen its sales volumes grow dramatically. In the June quarter, sales reached 62.4 lakh units, a significant rise from just 7,90,000 units sold in the same period last year. This surge in demand underscores the product's market acceptance and its role in driving the company's profitability.

Leadership Perspective

Sriram Natarajan, Executive Director and CEO of Molbio Diagnostics, expressed optimism about the company's trajectory. "FY27 is a milestone year for Molbio, marking our transition to a listed company," Natarajan stated. He highlighted the company's strong start to the fiscal year with healthy growth in both revenue and profitability.

Molbio Diagnostics' impressive financial results reflect the company's strategic focus on expanding its diagnostic solutions in the healthcare market. As the demand for rapid and reliable testing solutions continues to grow, the company is well-positioned to capitalize on these opportunities.